ProCE Banner Activity

LACEWING: Phase III Study of Gilteritinib + Azacitidine vs Azacitidine for Patients With Newly Diagnosed FLT3-Mutated AML Ineligible for Intensive Induction Chemotherapy

Slideset Download
Conference Coverage
Phase III study results show significantly higher composite complete remission rates but similar overall survival with gilteritinib + azacitidine vs azacitidine alone in patients with newly diagnosed FLT3-mutated AML ineligible for intensive induction chemotherapy.

Released: December 21, 2021

Expiration: December 20, 2022

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Daiichi Sankyo, Inc.


Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation